WHAT IS CLAIMED IS:

1. A composition comprising a first pharmaceutically acceptable agent which comprises a chelate complex of at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent which comprises at least one nucleoside / nucleotide analog HBV polymerase inhibitor for use in treating HBV infection or HBV / HDV co-infection in a subject.

2. A composition comprising a first pharmaceutically acceptable agent which comprises a chelate complex of one or more nucleic acid polymers selected from the following:

SEQ ID NO: 2;
SEQ ID NO: 10;
SEQ ID NO 13;
SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;
a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence AC;
a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence CA;
a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence TG and
a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence GT;

and a second pharmaceutically acceptable agent which comprises one or more of the following:

lamivudine;
adefovir dipivoxil;
entecavir;
telbivudine;
tenofovir disoproxil fumarate;
entricitabine;
clevudine;
besifovir;
tenofovir alafenamide fumarate;
AGX-1009;
elvucitabine;
lagociclovir valactate;

pradefovir mesylate;

valtorcitabine; and

any nucleoside/nucleotide analog which inhibits the HBV polymerase,

for use in the treatment of HBV infection or HBV / HDV co-infection.

3. The composition of claim 1 or 2, wherein the nucleic acid polymer further comprises at least one 2' ribose modification.

4. The composition of any one of claims 1-3, wherein the nucleic acid polymer further comprises all riboses having a 2' modification.

5. The composition of any one of claims 1-4, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification.

6. The composition of any one of claims 1-5, wherein the nucleic acid polymer further comprises all riboses having the 2' O methyl modification.

7. The composition of any one of claims 1-6, wherein the nucleic acid polymer further comprises at least one 5'methylcytosine.

8. The composition of any one of claims 1-7, wherein the nucleic acid polymer further comprises all cytosines present as 5'methylcytosine.

9. The composition of any one of claims 1-8, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification and at least one 5' methylcytosine.

10. The composition of any one of claims 1-9, wherein the nucleic acid polymer further comprises all riboses having the 2' O methyl modification and all cytosines present as 5'methylcytosine.

11. The composition of any one of claims 1-10, wherein the chelate complex is a calcium chelate complex.

12. The composition of any one of claims 1-10, wherein the chelate complex is a magnesium chelate complex.

13. The composition of any one of claims 1-10, wherein the chelate complex is a calcium / magnesium chelate complex.

14. The composition of any one of claims 1-13, wherein said first and second pharmaceutically acceptable agents are formulated within the same pharmaceutical composition.

15. The composition of any one of claims 1-13, wherein said first and second pharmaceutically acceptable agents are formulated within separate pharmaceutical compositions.

16. The composition of any one of claims 1-13, wherein said first and second pharmaceutically acceptable agents are to be administered simultaneously.

17. The composition of any one of claims 1-13, wherein said first and second pharmaceutically acceptable agents are to be administered by a different route.

18. The composition of any one of claims 1-17, wherein said first and second pharmaceutically acceptable agents are to be administered using one or more of the following: oral ingestion, aerosol inhalation, subcutaneous injection, intravenous injection and intravenous infusion.

19. Use of a first pharmaceutically acceptable agent which comprises a chelate complex of at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent which comprises at least one nucleoside / nucleotide analog HBV polymerase inhibitor in the manufacture of a medicament for treating HBV infection or HBV / HDV co-infection in a subject.

20. Use of a first pharmaceutically acceptable agent which comprises the chelate complex of one or more nucleic acid polymers selected from the following:

SEQ ID NO: 2;
SEQ ID NO: 10;
SEQ ID NO 13;
SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;
a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence AC;

a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence CA;

a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence TG and

a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence GT;

and a second pharmaceutically acceptable agent which comprises one or more of the following:

lamivudine;

adefovir dipivoxil;

entecavir;

telbivudine;

tenofovir disoproxil fumarate;

entricitabine;

clevudine;

besifovir;

tenofovir alafenamide fumarate;

AGX-1009;

elvucitabine;

lagociclovir valactate;

pradefovir mesylate;

valtorcitabine; and

any nucleoside / nucleotide analog which inhibits the HBV polymerase,

in the manufacture of a medicament for the treatment of HBV infection or HBV/HDV co-infection.

21. The use of any one of claims 19-20, wherein the nucleic acid polymer further comprises at least one 2' ribose modification.

22. The use of any one of claims 19-21, wherein the nucleic acid polymer further comprises all riboses having a 2' modification.

23. The use of any one of claims 19-22, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification.

24. The use of any one of claims 19-23, wherein the nucleic acid polymer further comprises all riboses having a 2' O methyl modification.

25. The use of any one of claims 19-24, wherein the nucleic acid polymer further comprises at least one 5'methylcytosine.

26. The use of any one of claims 19-25, wherein the nucleic acid polymer further comprises all cytosines present as 5'methylcytosine.

27. The use of any one of claims 19-26, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification and at least one 5'methylcytosine.

28. The use of any one of claims 19-27, wherein the nucleic acid polymer further comprises all riboses having the 2' O methyl modification and all cytosines present as 5'methylcytosine.

29. The use of any one of claims 19-28, wherein the chelate complex is a calcium chelate complex.

30. The use of any one of claims 19-28, wherein the chelate complex is a magnesium chelate complex.

31. The use of any one of claims 19-28, wherein the chelate complex is a calcium / magnesium chelate complex.

32. The use of any one of claims 19-31, wherein said first and second pharmaceutically acceptable agents are formulated within the same pharmaceutical composition.

33. The use of any one of claims 19-31, wherein said first and second agents are formulated within separate pharmaceutical compositions.

34. The use of any one of claims 19-31, wherein said first and second agents are formulated for a simultaneous administration.

35. The use of any one of claims 19-31, wherein said first and second agents are formulated for an administration by a different route.

36. The use of any one of claims 19-35, wherein said first and second agents are formulated for an administration using one or more of the following: oral ingestion, aerosol inhalation, subcutaneous injection, intravenous injection and intravenous infusion.